Craft
  • Home
  •  / 4D Molecular Therapeutics
4D Molecular Therapeutics

4D Molecular Therapeutics

IND-Enabling Stage Products

3

Q3, 2020

Revenue

$18 M

FY, 2021

Market Capitalization

$637.6 M

2023-01-23

4D Molecular Therapeutics Summary

Company summary

Overview
4D Molecular Therapeutics is a biotechnology company focused on the creation of gene therapy products to cure genetic diseases. Its Therapeutic Vector Evolution platform enables to create adeno-associated virus (AAV) gene therapy vectors, which deliver genes to any diseased tissue or organ in the body.
Type
Public
Status
Active
Founded
2013
HQ
Emeryville, CA, US | view all locations
Website
https://www.4dmoleculartherapeutics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Robert Fishman

    Robert Fishman, Chief Medical Officer

  • August Moretti

    August Moretti, Chief Financial Officer

  • Melissa Kotterman

    Melissa Kotterman, Vice President, Head of Discovery & Engineering, Co-Founder

  • Katy Barglow

    Katy Barglow, Vice President, Process and Analytical Development

Operating MetricsView all

Lead Optimization Stage Products

3

Q2, 2019

IND-Enabling Stage Products

3

Q3, 2020

Phase I Trials Products

3

Q3, 2020

LocationsView all

1 location detected

  • Emeryville, CA HQ

    United States

    5858 Horton St #455

4D Molecular Therapeutics Financials

Summary financials

Revenue (Q3, 2022)
$500.0K
Net income (Q3, 2022)
($25.7M)
EBIT (Q3, 2022)
($26.5M)

Footer menu